TG Therapeutics Inc (NASDAQ: TGTX) has a higher price-to-earnings ratio of 281.02x compared to its average ratio, The 36-month beta value for TGTX is at
TGTX has 36-month beta value of 2.30. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,”
Additionally, the 36-month beta value for TGTX is 2.31. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2
The stock of TG Therapeutics Inc (TGTX) has gone down by -0.32% for the week, with a 4.94% rise in the past month and a
© 2024, Powered by Smart TechOne
